Skip to content

Pharminent

Primary Menu
  • Home
    • Signal News
Light/Dark Button
Brief
  • Home
  • Pipeline
  • Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
  • Pipeline

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

BioSpace

Jefferies expects Moderna to have around seven commercial products in the coming years which, along with a projected 10% revenue growth, could help the company break even in 2028.

Read full story

pharminent June 26, 2026 (Last updated: June 26, 2026)

BioSpace

Jefferies expects Moderna to have around seven commercial products in the coming years which, along with a projected 10% revenue growth, could help the company break even in 2028.

Read full story

Post navigation

Previous: Immunai and Boehringer partner to identify T-cell targets
Next: Replimune gets early August decision date for twice-rejected melanoma drug

Related Stories

  • Pipeline

Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail

pharminent August 25, 2026
  • Pipeline

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

pharminent August 11, 2026
  • Pipeline

Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

pharminent August 11, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.